PCSK9 inhibitor therapy: delayed-onset cutaneous reactions
DOI:
https://doi.org/10.15277/bjd.2023.419Keywords:
PCSK9-inhibitor, delayed cutaneous reactionReferences
Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardio- vascular outcomes after acute coronary syndrome. N Engl J Med 2018;379(22):2097-2107. https://doi.org/10.1056/NEJMoa1801174
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376(18):1713-22. https://doi.org/10.1056/NEJMoa1615664
Thomaidou E, Ramot Y. Injection site reactions with the use of biological agents. Dermatol Ther 2019;32(2):e12817. https://doi.org/10.1111/dth.12817
Published
Issue
Section
License
Manuscripts published in the June 2024 edition and after in the BJD have been published in open access under a Creative Commons Attribution 4.0 International License and available at https://www.bjd-abcd.com. Prior year articles are available free of charge via our website.